Abstract: An aqueous suspension of pure 5-aminosalicylic acid adapted for rectal administration is rendered storage stable against color formation by storing the suspension in a single dose polyethylene bottle adapted for rectal administration of the suspension, in a substantially oxygen-free atmosphere and in the presence dissolved therein of up to about 0.25% of bisulfite and protecting the suspension from exposure to atmospheric oxygen during storage by sealing the plastic bottle, in a substantially oxygen-free atmosphere, in a plastic pouch having a low oxygen transmission rate.
Abstract: A new class of solid pharmaceutical formulations enables the attainment of slow, zero order in vivo release of a wide range of pharmaceutically active ingredients upon oral administration. A broad range of release rates can be preselected by suitable adjustments of tablet properties. The formulations are based upon control of active ingredient release from the surface of the tablet via a controlled surface erosion mechanism. These compositions comprise:(a) an effective amount in the range of 10-90 wt. % of a pharmacologically active compound having a water solubility (20.degree. C.) of 1/5-1/1000 (w/w);(b) 1-40 wt. % of a compound which is pharmaceutically acceptable in oral compositions and has a water solubility (20.degree. C.) of 1/1-1/40 (w/w);(c) 2-20 wt. % of a compound which is pharmaceutically acceptable in oral compositions and has a water solubility (20.degree. C.) of 1/1-1/10 (w/w);(d) an amount in the range of 0.05-1.0 wt.
Abstract: A new class of solid pharmaceutical formulations enables the attainment of slow, zero order in vivo release of a wide range of pharmaceutically active ingredients upon oral administration. A broad range of release rates can be preselected by suitable adjustments of tablet properties. The formulations are based upon control of active ingredient release from the surface of the tablet via a controlled surface erosion mechanism. These compositions comprise:(a) an effective amount in the range of 10-90 wt % of a pharmacologically active compound having a water solubility (20.degree. C.) of 1/5-1/500 (w/w);(b) 1-40 wt % of a compound which is pharmaceutically acceptable in oral compositions and has a water solubility (20.degree. C.) of 1/1-1/40 (w/w);(c) 2-20 wt % of a compound which is pharmaceutically acceptable in oral compositions and has a water solubility (20.degree. C.) of 1/1-1/10 (w/w);(d) an amount in the range of 0.05-1.
Abstract: Psyllium powder is rendered substantially instantly and uniformly dispersible in water by wetting the psyllium particles with an alcoholic solution of at least one of polyethylene glycol and polyvinylpyrrolidone and granulating the thus-coated particles. Polyvinylpyrrolidine in the coating reduces the friability of the granules.
Abstract: A pharmaceutical composition in tablet form for oral administration comprises:(a) 30-90% by weight of an active ingredient having a water solubility (20.degree. C.) of about 1/10-1/500 (w/w);(b) 1-40% by weight of an excipient which is pharmaceutically acceptable in oral tablets and which has a water solubility (20.degree. C.) of about 1/1-1/20 (w/w);(c) 0-20% by weight of a binder which is pharmaceutically acceptable in oral tablets;(d) 0-50% by weight of an excipient which is pharmaceutically acceptable in oral tablets and which has a water solubility (20.degree. C.) of about 1/1-1/5 (w/w);(e) 0.5-5% by weight of a die wall lubricant pharmaceutically acceptable in oral tablets;(f) 0-5% by weight of a surface active agent pharmaceutically acceptable in oral tablets; and(g) 0-1.0% by weight of a disintegration agent pharmaceutically acceptable in oral tablets;whereby the active ingredient has a slow in vivo release rate due to controlled surface erosion of the tablet.